In an exclusive interview at the BioPharma Ambition Conference 2016 in Dublin, Sir Andrew Dillon, founding CEO of the UK National Institute for Health and Care Excellence (NICE), shares his thoughts on the establishment of NICE in 1999, transparency and the evaluation of cost-effectiveness as the organization’s hallmarks, the dialogue it is establishing between all healthcare stakeholders within the UK, and the need for healthcare systems to be clear on their priorities and constraints.
Sir Dillon, you set up NICE in 1999 as the National Institute for Clinical Excellence and have seen its evolution since. What have been some key milestones?
"One of NICE’s hallmarks is that that we have always been prepared to explain our reasoning and evaluation process to patients, companies and the public, usually through relevant media channels."
